Success Metrics

Clinical Success Rate
62.5%

Based on 5 completed trials

Completion Rate
63%(5/8)
Active Trials
0(0%)
Results Posted
120%(6 trials)
Terminated
3(38%)

Phase Distribution

Ph phase_2
8
100%

Phase Distribution

0

Early Stage

8

Mid Stage

0

Late Stage

Phase Distribution8 total trials
Phase 2Efficacy & side effects
8(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

62.5%

5 of 8 finished

Non-Completion Rate

37.5%

3 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(5)
Terminated(3)

Detailed Status

Completed5
Terminated3

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
62.5%
Most Advanced
Phase 2

Trials by Phase

Phase 28 (100.0%)

Trials by Status

terminated338%
completed563%

Recent Activity

0 active trials
Showing 5 of 8
completedphase_2

Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis

NCT01369498
completedphase_2

Study of Simtuzumab in HIV and/or Hepatitis C- Infected Adults With Liver Fibrosis

NCT01707472
completedphase_2

Simtuzumab (GS-6624) in the Prevention of Progression of Liver Fibrosis in Adults With Primary Sclerosing Cholangitis (PSC)

NCT01672853
terminatedphase_2

Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

NCT01479465
terminatedphase_2

Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF)

NCT01769196
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT01369498Phase 2

Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis

Completed
NCT01707472Phase 2

Study of Simtuzumab in HIV and/or Hepatitis C- Infected Adults With Liver Fibrosis

Completed
NCT01672853Phase 2

Simtuzumab (GS-6624) in the Prevention of Progression of Liver Fibrosis in Adults With Primary Sclerosing Cholangitis (PSC)

Completed
NCT01479465Phase 2

Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Terminated
NCT01769196Phase 2

Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF)

Terminated
NCT01759511Phase 2

Long-Term Safety Study of GS-6624 in Adults With Idiopathic Pulmonary Fibrosis (IPF)

Terminated
NCT01472198Phase 2

A Study to Evaluate the Efficacy and Safety of Simtuzumab Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Completed
NCT01452308Phase 2

Pilot Study of Simtuzumab in the Treatment of Liver Fibrosis

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8